Barclays Raises Encompass Health (NYSE:EHC) Price Target to $101.00

Encompass Health (NYSE:EHC) had its price objective boosted by Barclays from $95.00 to $101.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 30.00% from the company’s previous close.

A number of other research firms have also recently commented on EHC. Mizuho upped their target price on shares of Encompass Health from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 9th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Truist Financial upped their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Friday, February 9th. Stephens reaffirmed an “overweight” rating and issued a $85.00 target price on shares of Encompass Health in a research report on Tuesday, January 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Encompass Health presently has a consensus rating of “Buy” and an average price target of $83.22.

Encompass Health Trading Up 1.2 %

Shares of EHC stock opened at $77.69 on Thursday. The company’s 50-day moving average price is $74.10 and its 200-day moving average price is $68.80. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. The stock has a market cap of $7.78 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 1.42 and a beta of 0.93. Encompass Health has a twelve month low of $52.32 and a twelve month high of $78.11.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.12. The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. As a group, equities analysts predict that Encompass Health will post 3.96 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

Hedge funds have recently added to or reduced their stakes in the stock. Principal Securities Inc. purchased a new position in Encompass Health in the fourth quarter valued at approximately $25,000. Benjamin F. Edwards & Company Inc. increased its stake in Encompass Health by 360.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after purchasing an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. purchased a new position in Encompass Health in the fourth quarter valued at approximately $30,000. GAMMA Investing LLC purchased a new position in shares of Encompass Health during the fourth quarter worth approximately $33,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Encompass Health during the third quarter worth approximately $35,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.